Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study
Journal of Bone and Mineral Research, 07/26/2013Eastell R et al.
The aim of this study was to examine the efficacy and safety of 24months treatment with ONO–5334 and to assess the effect of treatment cessation over 2months. Cathepsin K inhibition with ONO–5334 resulted in decreases in most resorption markers over 2 years, but did not decrease most bone formation markers. This was associated with an increase in BMD; the effect on biochemical markers was rapidly reversible on treatment cessation.
The authors studied 197 postmenopausal women with osteoporosis or osteopenia with one fragility fracture.
Patients were randomised to ONO-5334 50 mg twice daily, 100 mg or 300 mg once daily, alendronate 70 mg once weekly (positive control) or placebo for 24 months.
After 24 months, all ONO-5334 doses were associated with increased bone mineral density (BMD) for lumbar spine, total hip and femoral neck (p < 0.001).
ONO-5334 300 mg significantly suppressed the bone-resorption markers urinary (u) NTX and serum and uCTX-I throughout 24 months of treatment, and to a similar extent as alendronate; other resorption marker levels remained similar to placebo (fDPD for ONO-5334 300 mg qd) or were increased (ICTP, TRAP5b, all ONO-5334 doses).
Levels of B-ALP and PINP were suppressed in all groups (including placebo) for approximately 6 months, but then increased for ONO-5334 to close to baseline levels by 12–24 months.
On treatment cessation, there were increases above baseline in uCTX-I, uNTX and TRAP5b, and decreases in ICTP and fDPD.
There were no clinically relevant safety concerns.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.